-
Weight reducing version of semaglutide officially launched in China
Novo Nordisk announced on the 17th that Novo Nordisk, the world's first and currently the only glucagon like peptide-1 receptor agonist (GLP-1) weekly formulation for long-term weight management, has ... -
Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
The safety issues of compound generic drugs of semaglutide preparations are attracting attention. At the beginning of this month, the FDA (US Food and Drug Administration) warned that on August 14th ... -
The Battle of Weight Loss Drugs Begins: Smegglutide's Obesity Indications Approved in China
Recently, there has been new news in the field of GLP-1 (glucagon like peptide-1) weight loss. Novo Nordisk announced that the National Medical Products Administration (NMPA) has approved the marketi ... -
Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
21st Century Business Herald reporter Ji Yuanyuan reports from Shanghai Recently, the first injectable version of Smegglutide for long-term weight management, Novoying&Co., Ltd; reg; Finally, it was ... -
Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
On June 25th, the National Medical Products Administration (NMPA) approved the marketing application of Novo Nordisk's Novo Nordisk developed and produced Novo Nordisk's Novo Nordisk Injection (for l ... -
How effective is the drug supply process initiated by Novo Nordisk for the approved slimming version of Smegglutide in China?
Novo Nordisk Star Product Smegglutide has been approved in China for long-term weight loss management. On June 25th, Novo Nordisk announced that the National Medical Products Administration (NMPA) ha ... -
Novo Nordisk responds that semaglutide may cause male impotence
On June 4th, Novo Nordisk China told reporters that according to approved US prescription information or EU product feature summaries, sexual dysfunction is not a side effect mentioned in the Wegovy ... -
Can Smegglutide Help Quit Alcohol? Novo Nordisk's latest liver disease research will provide answers
According to the latest information from Clinical Trials. gov, Novo Nordisk will launch a phase II clinical trial on May 20th to evaluate the effects of three drugs, including Smegglutide, on liver f ... -
Longest Clinical Study of Smegglutide Published: Continuous Four Years of Medication Can Maintain 10% Weight Loss
[The longest clinical study of Smeglutide was published: it can maintain a weight loss of 10% after four years of medication] Star weight loss therapy Smeglutide manufacturer Novo Nordisk displayed t ... -
Novo Nordisk's new weight loss oral medication is applying for clinical efficacy or surpassing smeglutide in China
On April 10th, the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration of China announced that the clinical trial application for the Class 1 new oral ...- Ty奇葩罗牛山831
- 2024-4-11 19:03
- 支持
- 反对
- 回复
- 收藏
-
The first domestically produced Smegglutide has submitted a marketing application, but it is still far from being used for weight loss
In the current hot development of GLP-1 drugs, veteran players in the hypoglycemic field, East China Medicine, have accumulated numerous pipelines and are one of the domestic companies that cannot be ... -
Novo Nordisk: Positive progress made in reducing the risk of kidney disease with Smegglutide injections
On March 5th, Danish time, Novo Nordisk announced that its widely used semaglutide injection has made positive progress in treating kidney disease in a double-blind trial called FLOW. Compared with t ... -
Smegglutide's 2023 revenue is $21.2 billion, with a 407% increase in the lightweight version of Wegovy
On January 31st, Novo Nordisk released its 2023 results, with a total annual revenue of DKK 232.261 billion (approximately USD 33.771 billion), a year-on-year increase of 31%; The operating profit wa ... -
First in China! Oral version of Smegglutide approved for marketing
On January 26th, Red Star Capital Bureau reported that according to the latest announcement on the official website of the National Medical Products Administration, Novo Nordisk's GLP-1 analogue, Meg ... -
The big news of "weight loss miracle drug"! Oral Smegglutide Approved for Market in China
According to the information released by the State Drug Administration on January 26, Smeglutide tablets under Novo Nordisk (China) Pharmaceutical Co., Ltd. have been approved for marketing to treat ...